Enzymatica (OM:ENZY) - Stock Price, News & Analysis

ENZY Stock Overview

A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.

About the company

ENZY fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 102.75% per year

Trading at good value compared to peers and industry

Risk Analysis

Does not have meaningful revenue (SEK45M)

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have a meaningful market cap (SEK347M)

+ 1 more risk

Enzymatica AB (publ) Competitors

Orexo

OM:ORX

SEK 568.6m

Corline Biomedical

OM:CLBIO

SEK 272.9m

IRLAB Therapeutics

OM:IRLAB A

SEK 806.6m

PEPTONIC medical

NGM:PMED

SEK 92.1m

Price History & Performance

Summary of all time highs, changes and price drops for Enzymatica
Historical stock prices
Current Share Price	SEK 2.00
52 Week High	SEK 4.43
52 Week Low	SEK 1.93
Beta	-0.0091
11 Month Change	-19.35%
3 Month Change	-42.03%
1 Year Change	-30.43%
33 Year Change	-81.65%
5 Year Change	-58.51%
Change since IPO	-72.97%

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 20

Recent updates

Shareholder Returns

	ENZY	SE Pharmaceuticals	SE Market
7D	-24.8%	-2.6%	-1.8%
1Y	-30.4%	75.7%	14.4%

Return vs Industry: ENZY underperformed the Swedish Pharmaceuticals industry which returned 75.3% over the past year.

Return vs Market: ENZY underperformed the Swedish Market which returned 14.4% over the past year.

Price Volatility

Is ENZY's price volatile compared to industry and market?
ENZY volatility
ENZY Average Weekly Movement	12.3%
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.6%
10% least volatile stocks in SE Market	3.6%

Stable Share Price: ENZY's share price has been volatile over the past 3 months.

Volatility Over Time: ENZY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2007	16	Claus Egstrand	www.enzymatica.se

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care.

Enzymatica AB (publ) Fundamentals Summary

How do Enzymatica's earnings and revenue compare to its market cap?
ENZY fundamental statistics
Market cap	SEK 346.76m
Earnings (TTM)	-SEK 55.95m
Revenue (TTM)	SEK 44.95m

7.7x

P/S Ratio

-6.2x

P/E Ratio

Is ENZY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENZY income statement (TTM)
Revenue	SEK 44.95m
Cost of Revenue	SEK 16.19m
Gross Profit	SEK 28.76m
Other Expenses	SEK 84.72m
Earnings	-SEK 55.95m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)	-0.32
Gross Margin	63.99%
Net Profit Margin	-124.47%
Debt/Equity Ratio	38.7%

How did ENZY perform over the long term?

See historical performance and comparison

ENZY Stock Overview

Rewards

Risk Analysis

Enzymatica AB (publ) Competitors

OM:ORX

SEK 568.6m

OM:CLBIO

SEK 272.9m

OM:IRLAB A

SEK 806.6m

NGM:PMED

SEK 92.1m

Price History & Performance

Recent News & Updates

Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million.

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Second quarter 2024 earnings released: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023)

Independent Director recently bought kr4.6m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days

Recent updates

Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million.

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Second quarter 2024 earnings released: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023)

Independent Director recently bought kr4.6m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2026

New major risk - Financial position

First quarter 2024 earnings released: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023)

New minor risk - Shareholder dilution

Independent Director recently sold kr60k worth of stock

Enzymatica AB (publ) Announces Composition of Nomination Committee

New minor risk - Profitability

No longer forecast to breakeven

Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million.

Independent Director recently sold kr900k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.30 loss per share (vs kr0.45 loss in FY 2022)

Enzymatica AB (publ) to Report Fiscal Year 2023 Final Results on Apr 09, 2024

New major risk - Financial position

Enzymatica AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Consensus revenue estimates decrease by 30%

Third quarter 2023 earnings released: kr0.056 loss per share (vs kr0.085 loss in 3Q 2022)

Independent Chairman recently bought kr564k worth of stock

Enzymatica AB (publ) Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat

Enzymatica AB (publ) Announces New Study

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Second quarter 2023 earnings released: kr0.07 loss per share (vs kr0.10 loss in 2Q 2022)

Independent Director recently bought kr157k worth of stock

Independent Director recently bought kr157k worth of stock

Independent Chairman recently bought kr414k worth of stock

First quarter 2023 earnings released: kr0.091 loss per share (vs kr0.12 loss in 1Q 2022)

Independent Director recently sold kr1.5m worth of stock

Forecast to breakeven in 2025

Consensus revenue estimates decrease by 15%

Full year 2022 earnings released: kr0.45 loss per share (vs kr0.31 loss in FY 2021)

Enzymatica AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Enzymatica AB (publ) to Report Nine Months, 2023 Results on Nov 07, 2023

No longer forecast to breakeven

Third quarter 2022 earnings released

Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 74.6622 million.

Consensus forecasts updated

Second quarter 2022 earnings released

Enzymatica AB (publ) Announces New Data from an Ongoing In-Vitro Study

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Enzymatica AB's Mouth Spray to Be Launches in Turkey

Chairman recently bought kr1.7m worth of stock

Enzymatica and Sanofi Launches Mouth Spray in Mexico

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Enzymatica AB to Report Fiscal Year 2021 Final Results on Mar 31, 2022

Independent Director recently sold kr4.0m worth of stock

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Forecast breakeven date pushed back to 2023